Top Pick Over NVDA: Eli Lilly (LLY), Hidden Gem of Wall Street?
- Publication Date: 02/26/2024
Executive Summary
In this analysis, we turn the spotlight on Eli Lilly, a globally recognized company that has flown under the radar despite its commendable performance and significant contributions to global needs. Mirroring NVDA's growth since 2018, Eli Lilly distinguishes itself with its resilience during turbulent market periods. A prime example is 2022, a year when NVDA's stock value plummeted by nearly 50%, whereas Eli Lilly not only weathered the storm but also ended the year on a high note with impressive gains. This remarkable stability amidst volatility has gone largely unnoticed by Wall Street, yet it signals Eli Lilly's potential for sustained growth. The company's trajectory points towards a future where it could stand as the world's leading company by market capitalization. Here, we present a concise overview of Eli Lilly's potential, a giant in the making that Wall Street seems to overlook.
Eli Lilly and NVDA stock price comparison chart since 2018
The Long-Term Potential of Eli Lilly
In the swiftly evolving pharmaceutical landscape, Eli Lilly stands out not just for its storied history of innovation but also for its robust approach to tackling some of the most pressing health challenges of our times. As investors and industry watchers seek stable yet growth-oriented opportunities, Eli Lilly emerges as a beacon of potential. This article delves into the facets of Eli Lilly that underscore its promising horizon, particularly through the lens of its financial resilience, innovative pipeline, and strategic market positioning.
A Legacy of Innovation
At the heart of Eli Lilly's success lies a relentless pursuit of innovation. With a foundation dating back to the late 19th century, the company has been at the forefront of medical breakthroughs, from the mass production of insulin to the development of life-saving cancer therapies. Today, Eli Lilly continues to push boundaries, dedicating a significant portion of its resources to R&D, which has cultivated a rich pipeline of potential blockbusters, especially in areas like diabetes, oncology, and neurodegeneration.
ELI LILLY'S R&D- Driven Product Growth
Eli Lilly has several groundbreaking medicines in its pipeline that are poised to contribute significantly to its growth. Among these, notable mentions include treatments for chronic kidney disease, early Alzheimer’s disease, obesity, atopic dermatitis, and mantle cell lymphoma, reflecting the company's diverse and innovative approach to addressing critical health issues.
1-Empagliflozin
This drug for chronic kidney disease and Donanemab for early Alzheimer’s disease are set for regulatory submissions in the U.S., Europe, and Japan. Donanemab, in particular, has garnered attention for its potential in slowing the progression of Alzheimer's disease, a condition for which there is a dire need for effective treatments.
2-Tirzepatide
It is for atopic dermatitis is slated for submission in Japan, targeting a chronic condition that affects a substantial portion of the population with its debilitating dermatological symptoms.
3-Pirtobrutinib
It is a therapy for mantle cell lymphoma, is highlighted as a major growth driver. This reflects Eli Lilly's strengthened presence in oncology, particularly following the acquisition of Loxo Oncology, which has bolstered its portfolio with high-conviction assets like Verzenio®, Retevmo®, and pirtobrutinib itself.
These developments, coupled with the expected launches of donanemab, pirtobrutinib, mirikizumab, and lebrikizumab, along with the 2022 diabetes launch Mounjaro, are central to Eli Lilly's strategy for delivering innovative medicines to meet significant unmet patient needs. This diverse pipeline not only highlights Eli Lilly's robust investment in research and development but also its potential for sustained growth driven by these key products​
For insights into Eli Lilly's latest performance as of February 2024, consider exploring the Forbes article detailing the company's latest earnings release. This coverage offers a basic overview of their financial outcomes, highlighting key achievements and projections.
Spotlight on Eli Lilly's Valuation
Eli Lilly's stock valuation reflects its status as a heavyweight in the pharmaceutical industry, with a current market cap around $730.53 billion and an enterprise value of $752.83 billion. The company's valuation ratios reveal a high trailing PE ratio of 132.68 and a forward PE ratio of 60.73, indicating significant investor expectations for future earnings growth. The PS (Price to Sales) ratio stands at 21.41, underscoring the premium investors are willing to pay for Eli Lilly's revenue compared to its market cap.
Eli Lilly has demonstrated substantial growth, with a 52-week price increase of approximately 134.96%, showcasing strong investor confidence and market performance.
Navigating Market Dynamics
The global pharmaceutical industry is no stranger to volatility, shaped by regulatory shifts, patent cliffs, and the ever-present specter of competition. Yet, Eli Lilly's strategic maneuvers, including its adept navigation through 2022's tumultuous markets, signal a company not just surviving but thriving amidst challenges. When peers like NVDA faced stark downturns, Eli Lilly demonstrated remarkable financial health, buoyed by its diversified portfolio and strategic investments in next-generation treatments.
Eli Lilly has an alpha of 0.33, indicating that it performed 0.33% better than the benchmark index. Its beta is 0.27, suggesting the stock has lower volatility compared to the market​. Eli Lilly stands out as a unique large-cap growth investment, distinguished by its remarkable expansion coupled with a notably low beta. The provided chart succinctly illustrates this dynamic, showcasing the stock's growth trajectory against its low volatility, and highlighting its exceptional performance in the market.
Market Behavioral Perspective: Eli Lilly versus NVDA
The contrast in market reactions to Eli Lilly and NVIDIA underscores the impact of investor psychology. NVIDIA's tech advancements capture widespread attention, creating a herd mentality that boosts its stock, while Eli Lilly's achievements in developing a strong drug pipeline and delivering solid returns with less volatility go relatively unnoticed, making it a potential 'hidden gem.' This reflects a market bias towards certain sectors, risking imbalance if investors overly concentrate on one area, a phenomenon akin to destabilizing a ship by overcrowding one side, highlighting the dangers of missing the opportunity mentality.
Elevated media coverage for Eli Lilly, akin to NVIDIA, would likely heighten investor interest, potentially elevating its stock price. However, while increased visibility could positively adjust its market valuation, it might also introduce volatility, swaying the stock with market sentiment rather than fundamental value, creating a possibly unstable market dynamic for Eli Lilly.
Eli Lilly, despite having lower volatility and media attention compared to NVIDIA, has managed to achieve a performance level nearly on par with NVIDIA. This suggests Eli Lilly offers a more stable and balanced growth trajectory, underlining its potential as a robust investment option with less exposure to market whims and media-induced fluctuations that produce behavioral investing risk.
The Future Looks Bright
Eli Lilly's future is illuminated by its forward-looking investments and a product pipeline that promises to address unmet medical needs. Its ventures into treatments for Alzheimer's disease and its continued dominance in diabetes care are just the tip of the iceberg. The pharmaceutical giant is poised to lead in both innovation and market expansion, leveraging emerging technologies and global demographic trends to ensure its growth.
Moreover, the company's financial indicators, from revenue growth to profit margins, echo its operational excellence. While the stock market is a terrain marked by uncertainty, Eli Lilly's consistent performance and strategic planning suggest a trajectory of sustained growth. Analysts, while cautious, have pointed to the company's resilience and the evergreen demand for healthcare as reasons for optimism.
Conclusion
As we look to the horizon, Eli Lilly embodies the rare blend of stability and innovation that makes it a compelling candidate for long-term investment. Its journey reflects a deep-rooted commitment to addressing the complexities of healthcare with scientific rigor and strategic acumen. For those looking to diversify their portfolios with a stock that offers both growth potential and resilience, Eli Lilly presents a compelling narrative.
Investors are encouraged to delve deeper into Eli Lilly's story, keeping an eye on its pipeline developments and market strategies. In the ever-changing world of pharmaceuticals, Eli Lilly's steadfast approach offers a beacon of growth potential and stability.
Warm Regards
Sam Sacli
Editor
CONTACT US
The Scholarch LLC
1111B Governors Ave. STE 7059 Dover, DE 19904
research@thescholarch.com
Disclaimer: The Scholarch Reports upholds the highest standards of integrity and transparency in all its publications. We unequivocally assert that the content within our research articles is authentic and genuine, steadfastly adhering to the principles of impartiality and objectivity. Our commentary and analysis are conducted disinterestedly, devoid of any personal or financial interests that might potentially skew our evaluations. It is our policy not to invest in the stock ideas we report on. Should an exception arise, it will be clearly disclosed at the conclusion of our reports or articles. The insights and assessments provided in our research articles and reports are the culmination of meticulous research, intended solely for informational and educational purposes. They are not promotional in nature and should not be interpreted as an endorsement or solicitation to buy or sell any stocks, financial products, or services. The content provided on our website or in our reports does not constitute investment advice or an endorsement of any specific investment strategy. While we endeavor to provide accurate and up-to-date information, The Scholarch LLC and its affiliates do not guarantee its completeness or accuracy. We shall not be held accountable for any losses incurred from reliance on this information. Past performance is not a reliable indicator of future results. Readers are strongly advised to conduct their own due diligence and consult with a professional advisor before making any investment decisions. The Scholarch LLC does not possess a financial advisory license and therefore does not offer personalized financial advice. This website and our reports may include links to third-party websites and information; The Scholarch LLC is not liable for their content or accuracy. We appreciate your trust in The Scholarch Reports. Thank you for reading our disclaimer.
